Aridis Pharmaceuticals Inc (ARDS) Given $28.25 Consensus Target Price by Analysts

Share on StockTwits

Aridis Pharmaceuticals Inc (NASDAQ:ARDS) has earned an average broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.

Brokers have set a one year consensus target price of $28.25 for the company and are anticipating that the company will post ($1.03) EPS for the current quarter, according to Zacks. Zacks has also given Aridis Pharmaceuticals an industry rank of 79 out of 255 based on the ratings given to related companies.

A number of research analysts recently weighed in on the stock. Maxim Group assumed coverage on shares of Aridis Pharmaceuticals in a research note on Tuesday, October 2nd. They issued a “buy” rating for the company. Northcoast Research assumed coverage on shares of Aridis Pharmaceuticals in a research note on Monday, September 10th. They issued an “outperform” rating and a $40.00 price objective for the company. Cantor Fitzgerald assumed coverage on shares of Aridis Pharmaceuticals in a research note on Monday, September 10th. They issued an “overweight” rating for the company. Northland Securities assumed coverage on shares of Aridis Pharmaceuticals in a research note on Monday, September 10th. They issued an “outperform” rating for the company. Finally, Laidlaw assumed coverage on shares of Aridis Pharmaceuticals in a research note on Monday, September 10th. They issued a “buy” rating and a $23.00 price objective for the company.

Aridis Pharmaceuticals stock opened at $12.62 on Thursday. Aridis Pharmaceuticals has a 1-year low of $11.25 and a 1-year high of $13.85.

Aridis Pharmaceuticals Company Profile

Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.

Featured Article: Stock Symbols Definition, Examples, Lookup

Get a free copy of the Zacks research report on Aridis Pharmaceuticals (ARDS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aridis Pharmaceuticals (NASDAQ:ARDS)

Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Starbucks Co.  Receives Average Recommendation of “Buy” from Brokerages
Starbucks Co. Receives Average Recommendation of “Buy” from Brokerages
Brokerages Expect Rexford Industrial Realty Inc  Will Post Quarterly Sales of $54.03 Million
Brokerages Expect Rexford Industrial Realty Inc Will Post Quarterly Sales of $54.03 Million
Uro  Trading Up 22% This Week
Uro Trading Up 22% This Week
Gold Poker Hits Market Cap of $863,224.00
Gold Poker Hits Market Cap of $863,224.00
Brokerages Anticipate Eventbrite Inc  to Post  Earnings Per Share
Brokerages Anticipate Eventbrite Inc to Post Earnings Per Share
QuickLogic Co.  Receives Consensus Rating of “Strong Buy” from Analysts
QuickLogic Co. Receives Consensus Rating of “Strong Buy” from Analysts


Leave a Reply

© 2006-2018 Ticker Report. Google+.